



Tosk, Inc.

Improving Outcomes for Cancer Patients

NOTE: For Distribution Only to Accredited Investors

September 2022



Task Overview

- Clinical Stage, Small Molecule Drug Discovery and Development Company
- Addressing Large, Unmet Medical Needs
 - ◆ >50% of All Cancers
- Experienced Management Team
 - ◆ Big Pharma
 - ◆ Multiple Startup Exits
- \$27 Million Funding to Date



Leadership Team

Management

Brian Frenzel, CEO



- ◆ Co-Founder of 3 Therapeutic and 1 Diagnostic Co.
 - Centaur (CEO, Acquired by RNVS)
 - Vesta (CEO, Chairman, Acquired by PFE)
 - Adeza (CEO, ADZA, Acquired by CYTC)
 - Genelabs (COO, GNLB)
- ◆ Dir. of Corp. Planning at Syntex
- ◆ Principal at Booz, Allen, Consultant at BCG
- ◆ Lt. USN Nuclear Power Program
- ◆ BS and MBA from Stanford



Bill Garland, PhD, VP R&D

- ◆ CEO, AngioGenex
- ◆ VP Pharmaceutical Development, Lpath
- ◆ 20 Years at Hoffmann-La Roche
- ◆ PhD, University of Washington



Steve Yanofsky, PhD, VP Research, Biology

- ◆ Director, Cell Biology, Amunix
- ◆ PhD / Post Doc, UCSF in Herb Boyer's lab

Board of Directors

Hal Crow, Chairman



- ◆ President and CEO of Hystagel, Inc.
- ◆ President and CEO of Aquintel, Inc.
- ◆ Director, Far East at Syntex

Charles Garvin



- ◆ CEO, Riptide Bioscience
- ◆ Principal at Palisades Associates
- ◆ Chairman or Controlling Interest Director
 - TVC Communications, Riviera Trading, EK Holdings
- ◆ Principal Beta Group, VP BCG
- ◆ JD and BA from Harvard, Rhodes Scholar, Oxford

Advisory Boards

Scientific Advisory Board

- **Larry Marsh, PhD***
 - ◆ UC Irvine
 - Prof. Molecular, Cell and Developmental Biology
- **Giuseppe Pizzorno, PhD, PharmD****
 - ◆ Associate Dean for Research, University of Tennessee
 - ◆ Chief Research Officer, Erlanger Health System
- **David Shuman, DVM**
 - ◆ Attending Veterinarian
 - ◆ President of Westside Animal Hospital, Santa Cruz
- **William Sullivan, PhD***
 - ◆ UC Santa Cruz
 - Prof. Molecular, Cell and Developmental Biology
- **Jeffrey Thomas, PhD***
 - ◆ Texas Tech Medical School
 - Prof. Cell Biology and Biochemistry

Medical Advisory Board













- **Steven Deitcher, MD**
 - ◆ CEO, RadImmune Therapeutics, Inc.
- **Joel Epstein, DMD**
 - ◆ Prof. Cancer Dentistry, Oschin Cancer Inst., Cedars-Sinai
 - ◆ Medical Dir., Dental Oncology, City of Hope Cancer Center
- **Ian Ferrier, MD**
 - ◆ Managing Director, Sibelius, LLC
- **Paul Page, MD**
 - ◆ Radiation Oncologist, South Sacramento Oncology Center
- **Ravi Patel, MD**
 - ◆ Director Comprehensive Cancer Center, Bakersfield
 - ◆ Assoc. Professor of Medicine, UCLA

* Recognized leader in Drosophila research

** Recognized leader in uridine metabolism



Four Proprietary, Small Molecule Drugs in Development

Asset	Target	Research	IND Candidate	Phase 1	Phase 2	Phase 3
TK-90	Mucositis & Pulmonary Fibrosis side effect prevention for chemotherapy & radiation therapy. Also, potential applications outside of cancer.					
TK-39	Cardiotoxicity side effect prevention. Also, potential applications outside of cancer.				Undergoing formulation	
TK-88	.Nephrotoxicity side effect prevention. Likely will also prove effective for peripheral neuropathy & hearing loss.			Undergoing lead optimization		
TK-KRAS	KRAS positive cancers, representing approximately 30% of all cancer.			Undergoing lead optimization		



TK-90 for Mucositis Prevention

Mucositis is a dose limiting, debilitating, and potentially fatal side effect

- Mucositis Causes:
 - ◆ Weight Loss, Mouth Ulcers, Abdominal Pain, Vomiting, Diarrhea, Potentially Fatal Infection
- Cancer Targets:
 - ◆ Methotrexate
 - Head & Neck Cancer
 - Leukemia
 - ◆ 5-FU
 - Colorectal Cancer
 - Breast Cancer
 - Pancreatic Cancer
 - ◆ Radiation Therapy
 - Head & Neck Cancer
 - ◆ Bleomycin (Pulmonary Fibrosis)
 - Lymphoma
 - Ovarian Cancer
 - Cervical Cancer



TK-90 has Successfully Completed 3 Human Clinical Studies

■ Phase 1a

- ◆ 15 Volunteers
 - No Drug-related Side Effects

■ Phase 1b

- ◆ 27 Patient Dose Ranging Study for Chemotherapy-Induced Mucositis Prevention
 - No Drug-related Side Effects
 - Two Highest Doses Fully Protective

■ Phase 2a

- ◆ 22 Patient Placebo Controlled Study for Chemotherapy-Induced Mucositis Prevention
 - No Drug-related Side Effects
 - TK-90 Fully Protective

■ Results Consistently Show TK-90 Safe and Effective




TK-90 Protection Demonstrated by NCI Mucositis Score

Head and Neck Cancer Patients Administered 45 mg/m² MTX Weekly for 4 Weeks w/ Placebo or 45 mg/kg TK-90. NCI Mucositis Score Avg. of 24 and 48 Hours Post-dose.

Score	National Cancer Institute (NCI) Definition
0	No objective findings
1	Asymptomatic or mild symptoms; intervention not indicated
2	Moderate pain; not interfering with oral intake; modified diet indicated
3	Severe pain; interfering with oral intake
4	Life-threatening consequences; urgent intervention indicated

[Source]: NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.

* p < .05
 ** p < .001
 *** p < .0001




TK-90 Protection Demonstrated by WHO Mucositis Score

Head and Neck Cancer Patients Administered 45 mg/m² MTX Weekly for 4 Weeks w/ Placebo or 45 mg/kg TK-90. WHO Mucositis Score Avg. of 24 and 48 Hours Post-dose.

Score	World Health Institute (WHO) Definition
0	No objective findings
1	Soreness with erythema
2	Erythema, ulcers, can eat solids
3	Ulcers, liquid diet only
4	Alimentation not possible

[Source]: World Health Organization

* p < .05
 ** p < .0015
 *** p < .0001



TK-90 Has an Impressive Pharmaceutical Product Profile



- Patented, New Chemical Entity
- Novel Mechanism of Action
- Inexpensive to Produce
 - ◆ Available to a Worldwide Market, not Just the Affluent
 - ◆ Reducing Overall Cost of Care
- Extremely Safe
 - ◆ No Drug Related Side Effects Observed in Toxicology or Clinical Studies
- Oral and/or IV Dosing
 - ◆ Use in Hospital, Clinic, and Home

TK-39 for Cardiotoxicity Prevention


- Target – Doxorubicin & Analogs
 - ◆ Widely Used for Leukemia, Lung, Breast, and Bladder Cancer
 - ◆ Particularly Effective Against Lymphoma
 - ◆ Causes Permanent Damage to Heart
 - Limits Lifetime Dose to 450-550 mg / m²
 - 3-5% Congestive Heart Failure in 2 Years
 - 25% Cardiomyopathy in 2 Years
- Other Applications
 - ◆ Herceptin® (trastuzumab)
 - HER2 Breast and Stomach Cancer
 - ◆ Perjeta® (pertuzumab)
 - HER2 Breast Cancer



TK-39 Protects Against Doxorubicin-Induced Cardiotoxicity in Biomarker Assay

CD-1 male mice (n=12/group);
Day 1: Doxorubicin 25mg/kg and TK ± 3 HR; Days 2-4: Single TK Dose; Day 5: cTnl ELISA; TK Dose = 0.1 and 1.0 mg/kg, ip.

Elevated serum concentration of cardiac troponin I (cTnl) is a highly sensitive and specific marker of myocardial damage.




*p < 0.03
**p < 0.01



TK-39 Protects Against Doxorubicin-Induced Cardiotoxicity in Functional Assay

Wistar male Rats (4 groups of 4). DOX 1mg/kg/wk Weeks 0-4, then 2mg/kg/wk. TK-39 iv 4mg/kg, Increased 50% weekly to a maximum of 15mg/kg/wk. Fraction Shortening Measured on Days 39-40 by one way ANOVA.

Fractional shortening (FS) is calculated by measuring the percentage change in left ventricular diameter during systole. It is measured in parasternal long axis view (PLAX) using M-mode. The end-systolic and end-diastolic left ventricular diameters are measured.



Tosk's IP Portfolio Includes 4 Issued and 10 Pending Patent Families

- *Drosophila* Drug Discovery Platform
 - ◆ Methods for KRAS Oncogene Inhibiting Pharmaceutical Compound Discovery
 - US Patent 10,660,318
- TK-90
 - ◆ Methotrexate Adjuvants to Reduce Toxicity
 - US Patents 7,998,967 / 8853227 / 9382287
 - ◆ Pending Patents for Other Cancer Indications, Pulmonary Fibrosis, and Liver Disease
 - ◆ Pending Patents for Mechanism of Action
- TK-39
 - ◆ Doxorubicin Adjuvants to Reduce Toxicity
 - US Patents 8,227,517 / 9,061,038 / 9,468,613
 - ◆ Follow-on Applications Planned to Extend Scope and Lifetime
- TK-KRAS
 - ◆ Pyrazolopyrimidine Modulators of RAS GTPase
 - US Patent 11,390,626



Cancer Drug Targets and Disease Applications

Tosk Drug	Target	Breast Cancer	Cervical Cancer	Colon Cancer	Endometrial Cancer	Head & Neck Cancer	Leukemia	Lung Cancer	Lymphoma	Ovarian Cancer	Pancreatic Cancer	Prostate Cancer	Skin Cancer	Testicular Cancer
TK-90	MTX	✓				✓	✓		✓			✓	✓	
	5-FU	✓		✓		✓					✓		✓	
	Radiation	✓	✓			✓	✓					✓		
	Bleomycin		✓			✓			✓	✓				✓
TK-39	DOX	✓			✓			✓	✓	✓	✓		✓	
TK-88	Cis/Carbo platin	✓	✓		✓	✓	✓	✓	✓	✓	✓		✓	
TK-KRAS	KRAS Protein		✓	✓		✓	✓	✓			✓		✓	

❖ \$10 Billion Worldwide Sales Potential

❖ Safer therapies will expand these markets



Frequently Asked Questions

- **How Have You Accomplished So Much with a Small Team?**
 - Highly Experienced Board and Executives
 - Active Group of Scientific and Medical Advisors
 - Low Overhead Implementation Using CROs

- **What Are Your Plans To Expand the Team?**
 - Chief Medical Officer for TK-90 Phase 2b/3
 - Chief Financial Officer for IPO Preparation
 - Support Staff



Frequently Asked Questions (Cont.)

- **TK-90 Results Are Impressive Despite Relatively Small Numbers of Patients**
 - Patient Numbers Statistically Powered by Preclinical Results and for Phase 2a, Phase 1b Results
- **Why No Publications?**
 - Stealth and Resource Allocation
 - Planning to Publish This Year on TK-90
- **Is Pipeline Diversified?**
 - Yes
 - Each Resulted from Separate Discovery Effort
 - Each Has Independent Structure, Mechanism, and Target
- **Markets Appear Crowded, Especially for Mucositis**
 - Mucositis Has Many Palliative Relief Products on Market and a Few New Product in Development
 - But None Comparable to TK-90 in Performance
 - Prophylactic Mucositis Opportunity Remains Very Open
 - Cardiotoxicity and Nephrotoxicity Have No Effective Competition



Investment Considerations

- Risks Mitigated
 - ◆ \$27 Million Raised to Date
 - ◆ Two Unique Discovery Platforms
 - ◆ Clinical Proof of Concept Drug Development Capability
 - ◆ Four Products in Pipeline, Addressing Large, Unmet Medical Needs
 - ◆ Risk Mitigated by uncorrelated Clinical Asset Portfolio
- Highly Levered Investment in Improving Outcomes for Cancer Patients, Worldwide
 - ◆ Low Cost, Small Molecule Drugs
 - ◆ Designed to Lower Overall Cost of Care
 - ◆ Platform Allows “Repeat Process” and Portfolio Expansion



Timeline: 18 Month Milestones

- TK-90
 - ◆ Initiate Phase 2b/3 Registration Study
 - ◆ Broaden Cancer Clinical Indications
 - Other Chemotherapy-Induced Mucositis
 - Radiation Therapy Induced Mucositis
 - ◆ Develop Oral Formulation
- File IND for TK-39 for Cardiotoxicity Prevention and Treatment
- Develop TK-KRAS Through IND-Enabling Studies
- Develop TK-88 for Nephrotoxicity Through IND-Enabling Studies
- Pharma Licensing Deal
- Achieve IPO / M&A



Risk Factors

An investment in the Shares involves a number of risks. You should carefully consider the following risks and other information in this Memorandum and information contained in the Subscription Agreement before purchasing the Shares. This investment is highly speculative, and you may lose all or a part of your investment.

Risks Related to the Company's Operations and Industry:

- Our risk management efforts may not be effective which could result in unforeseen losses.
- We are exposed to the risk of natural disasters, unusual weather conditions, pandemic outbreaks, political events, war and terrorism that could disrupt business and result in lower sales, increased operating costs and capital expenditures.
- We are susceptible to adverse economic conditions.
- We rely and expect to rely on a combination of confidentiality, assignment, and license agreements with our employees, consultants, and third parties with whom we have relationships, as well as intellectual property laws, to protect our proprietary rights.
- Security breaches and improper access to or disclosure of our data or user data, or other hacking and phishing attacks on our systems, could harm our reputation and adversely affect our business.
- The Company is obligated to pay certain fees and expenses.
- The Company has a limited operating history, which makes it hard to evaluate its ability to generate revenue through operations.
- We may not be able to raise additional funds if and when needed.
- To the extent that we seek to expand our operations and increase our reserves through acquisitions, we may experience issues in executing acquisitions or integrating acquired operations.
- The Company operates in an industry subject to a high degree of regulatory control, and there can be no guarantee that the Company will be able to achieve sufficient regulatory approvals to sell its products.
- When approved, the Company will rely on licenses and marketing and distribution agreements with other companies to sell its products.



Risk Factors

Risks Related to the Company and our Business:

- The Company may experience fluctuations in its quarterly results.
- Our financial condition and results of operation will depend on our ability to effectively manage future growth.
- Regulatory, legal and tax changes may adversely affect the Company.
- The Company is undertaking this Offering pursuant to a private offering exemption.
- There may be no recourse to the Company's assets.
- General economic conditions and recent events may affect the Company and its operations.
- Negative publicity could adversely affect our business and operating results.
- We may fail to implement our business plan.
- There may be unanticipated obstacles to the execution of the Company's business model.
- Management has broad discretion as to the use of proceeds.
- The Company's results are dependent on successful initiatives and acceptance by customers of the Company's products and services.
- Our operations overall may be impaired by the Coronavirus pandemic.
- Declining economic conditions could negatively impact our business.
- The Company is not profitable, has historically operated at a loss, and expects to continue to operate at a loss for the foreseeable future.
- It is difficult to accurately forecast future revenue and growth, resulting in considerable uncertainty in both.
- The Company operates in a highly competitive industry.
- The Company is dependent on current management, advisors, and other key personnel.
- We have a limited operating history and thus are subject to risks of business development.
- The Company's success and profitability is dependent on the Company's ability to protect its products, trade secrets, and other proprietary information cannot be assured.



Risk Factors

Risks Related to this Offering and the Shares:

- The offering price of the Shares has been determined arbitrarily.
- If the Company ceases operations the Shares will have limited or no value or use.
- There is a risk of uninsured losses.
- There is no assurance that purchasers of the Shares will receive a return on their investment.
- Investors may lack information for monitoring their investment.
- The Shares have no material history.
- Investing in private placements is risky.
- There may be adverse tax consequences for Investors upon certain future events.
- Prospective Investors must undertake their own due diligence.
- You have no ability to withdraw from your investment.
- While the stockholders have a right to vote thereon, the Board and the officers they designate will make all management decisions.
- If the Shares ever become transferable, such transactions may be irreversible, and, accordingly, losses due to fraudulent or accidental transactions may not be recoverable.
- Investors should expect to hold their Shares for an indefinite period of time.
- There is no public market for the Shares, so Investors may be unable to dispose of their investment.



DISCLOSURE AND FORWARD-LOOKING STATEMENTS

This presentation contains certain statements that may include 'forward looking statements' within the meaning of federal securities laws. All statements, other than statements of historical facts, included herein are 'forward-looking statements.' Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with and available from the Securities and Exchange Commission. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements. The financial information and data contained in this presentation is unaudited and does not conform to the Securities and Exchange Commission's Regulation S-X. This presentation includes certain estimated financial information and forecasts that are not derived in accordance with generally accepted accounting principles (GAAP), and which may be deemed to be non-GAAP financial measures within the meaning of Registration G promulgated by the Securities and Exchange Commission. The Recipient acknowledges that US securities laws prohibit any Person who has received from an issuer any material, non-public information from purchasing or selling securities of such issuer or from communicating such information to any other Person under circumstances in which it is reasonably foreseeable that such Person is likely to purchase or sell such securities

FOR ACCREDITED INVESTOR USE ONLY – DISCLAIMERS

This Investor Summary (this "Investor Summary") is being furnished by or on behalf of the Company based on information provided or furnished by the Company or from publicly available sources. Any information contained in this Investor Summary is being furnished for informational purposes only. The information contained herein is confidential and is provided for the exclusive use of the recipient and may not be reproduced, provided or disclosed to others, or used for any other purpose, without written authorization by JUSTLY Markets, LLC ("Advisors") and the Company, and upon request must be returned to the Company or Advisors. JUSTLY Markets, LLC ("JUSTLY") a Delaware limited liability, is a FINRA/SEC registered Broker Dealer in connection with any transaction involving the Company pertaining to the matters contained herein, and any recipient of this Investor Summary acknowledges and agrees to the agreement in connection with any transaction involving the Company pertaining to the matters contained herein. This Investor Summary is not intended to be and does not constitute financial advice or any other advice, is general in nature and not specific to any recipient. Recipients are responsible for their own investment research and investment decisions. This Investor Summary is for informational purposes only. Recipients should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained on this Investor Summary constitutes a solicitation, recommendation, endorsement, or offer by Advisors or any third-party service provider to buy or sell any securities or other financial instruments in this or in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction. All content in this Investor Summary is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this Investor Summary constitutes professional and/or financial advice, nor does any information in this Investor Summary constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. Advisors are not fiduciaries by virtue of any person's use of or access to this Investor Summary or the information contained herein. Recipients alone assume the sole responsibility of evaluating the merits and risks associated with the use of any information or other content in this Investor Summary before making any decisions based on such information or other content.



In exchange for using this Investor Summary, recipients agree not to hold Advisors, its affiliates or any third-party service provider liable for any possible claim for damages arising from any decision recipients make based on information or other content made available to recipients through this Investor Summary. This Investor Summary is provided on an “as is” basis without warranties of any kind, either express or implied, including but not limited to warranties of title or implied warranties of merchantability or fitness for a particular purpose. The disclaimers of liability contained herein apply to any damages or injury caused by any failure of performance, error, omission, interruption, deletion, defect, delay in operation or transmission, computer virus, communication line failure, theft or destruction or unauthorized access to, alteration of, or use of record, whether for breach of contract, tortious behavior, negligence, or under any other cause of action. Any recipient of this Investor Summary acknowledges that Advisors are not liable for the defamatory, offensive, or illegal conduct of other third parties, members, or other users of the Investor Summary. In no event will Advisors or any person or entity involved in creating, producing, or distributing content of this Investor Summary be liable for any direct, indirect, incidental, special, or consequential damages (including but not limited to lost profits or trading losses) arising out of the use of or inability to use this Investor Summary or out of the breach of any warranty. Advisors neither endorse nor are responsible for the accuracy or reliability of any opinion, advice, information or statement on this Investor Summary. Under no circumstances will Advisors be liable for any loss or damage caused by any recipient’s reliance on information obtained through the content on this Investor Summary. The information contained herein has not been independently verified, and neither the Company, Advisors nor their respective affiliates make any representation or warranty (expressed or implied) as to the accuracy or completeness of this Investor Summary or any statements, estimates or projections contained herein, and none of them will have any liability for any recipient’s use of this Investor Summary or any other oral, written, or other communications transmitted to the recipient in the course of its evaluation of the Company.

This Investor Summary includes certain forward-looking statements, estimates and projections provided by, and with respect to the anticipated future performance of the Company. In some cases, recipients can identify forward-looking statements by terminology such as “may”, “estimates”, “anticipates”, “intends”, “will”, “should”, “could”, “expects”, “believes”, or “predicts”. Such statements, estimates, and projections reflect various assumptions and elements of subjective judgment made by management concerning anticipated results, which are subject to business, economic, and competitive uncertainties and contingencies, many of which are beyond the control of the Company and which may or may not prove to be correct. This Investor Summary contains certain projected financial information that reflects management’s projections as to anticipated future results based upon assumptions that are inherently uncertain, including assumptions as to the size of the market in which it competes, general industry conditions, and other factors. The assumptions are based upon management’s judgment. As a result, no representation or warranty is made as to the feasibility of the projected financial information included in this Investor Summary. The only information that will have any legal effect will be that which is specifically represented or warranted in a definitive agreement relating to a transaction with the Company and executed on behalf of the Company and a third party. This Investor Summary is only being made available to parties who have signed and returned a non-disclosure agreement and recipients are therefore bound by the terms of such non-disclosure agreement in respect of all information contained herein. The Company and Advisors accept no liability whatsoever for the actions of third parties with respect to any re-distribution of the Investor Summary. Advisors anticipate receiving a fee from the Company in connection with the transaction contemplated herein. This Investor Summary is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction. This material is general and broad insofar as it does not have regard to the particular circumstances or needs of any specific person who may read it. Recipients should not regard this Investor Summary as a substitute for the exercise of their own judgment. The Company reserves the right to negotiate with one or more prospective third parties at any time and to enter into a definitive agreement relating to a transaction with the Company without prior notice to the recipient or other prospective third parties. Also, the Company reserves the right, at any time, to terminate the further participation in the investigation and process by any party and to modify any procedures without giving advance notice or providing any reason thereof. The Company also reserves the right during the evaluation period to take any action, whether within or outside the ordinary course of business. Neither this Investor Summary nor its delivery to recipients shall constitute or be construed to be an offer to sell any securities of the Company. Neither the Company nor Advisors expect to update or otherwise revise this Investor Summary or other materials supplied herewith.



For Additional Information



Paul Karrlsson-Willis

Chief Executive Officer
JUSTLY Markets, LLC
t: (321) 200 - 4675
e: pkarrlsson-willis@investjustly.com



Eugenio Briales Gomez-Tarragona

Vice President, Head of Capital Markets
JUSTLY Markets, LLC
t: (617) 852 - 4952
e: ebriales@investjustly.com

Securities offered through JUSTLY Markets, LLC, member of FINRA/SIPC, a registered broker/dealer and wholly owned subsidiary of Ideanomics, Inc.

